AOD-9604 — 5mg
Research-grade AOD-9604, a synthetic 16-amino-acid peptide fragment (Tyr-hGH 176-191) derived from the C-terminal domain of human growth hormone. Studied for selective lipolytic activity, adipose metabolism, and fat cell signaling independent of IGF-1 receptor activation. 5mg lyophilized powder, 99%+ purity verified by Janoshik Analytical via HPLC and mass spectrometry.
For laboratory research use only.
Not for human or veterinary use.
Not intended for diagnosis, treatment, cure, or prevention of any disease.
Use only in controlled laboratory settings by qualified personnel following appropriate safety procedures.
AOD-9604 (Anti-Obesity Drug 9604) is a synthetic hexadecapeptide corresponding to residues 176-191 of human growth hormone, with a tyrosine substitution at the N-terminus and an intramolecular disulfide bridge (Cys7-Cys14). Originally developed by Metabolic Pharmaceuticals Ltd. in Australia during the 1990s, AOD-9604 was designed to isolate growth hormone's lipolytic properties while excluding the broader metabolic and growth-promoting effects associated with full-length hGH. It completed six human clinical trials involving over 900 participants. AOD-9604 is frequently studied alongside Durham Peptides' metabolic research compounds including Semaglutide and Tirzepatide.
BENEFITS
Selective lipolytic activity — studied for fat metabolism independent of IGF-1 receptor activation
Growth hormone fragment — retains the hGH 176-191 lipolytic region without somatotropic effects
Disulfide-stabilized — Cys7-Cys14 bridge provides conformational stability
Extensive clinical history — studied in over 900 human subjects across Phase I-IIb trials
Distinct mechanism — operates independently of the hGH receptor
WHAT RESEARCHERS LOOK AT
β₃-adrenergic receptor upregulation in adipocyte models
Lipolysis and lipogenesis inhibition in white and brown adipose tissue
Comparative analysis vs. full-length hGH on lipolytic activity
IGF-1 independence and selective metabolic effects
Cartilage regeneration and joint biology in preclinical models
